ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2019
Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 110 citations in OpenAlex.
- Liposomal Nanoparticulate Drug Delivery Systems: Strategies to Destabilize Biological Membranes at the Target Tissue.International journal of nanomedicine · 2026Review
- pH-Sensitive Long-Circulating Nanoliposomes with CU1 for Effective Against Lung Cancer.International journal of nanomedicine · 2026Article
- Metformin-Loaded Fusogenic Liposome Improves the Therapeutic Efficacy and Safety of Doxorubicin in a Breast Cancer Treatment.ACS omega · 2025Article
- Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons.Pharmaceutics · 2025Review
- Encapsulation of doxorubicin in magnesium acetate liposomes as a pH-sensitive drug carrier for tumor therapy.iScience · 2025Article
- Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers · 2025Review
- Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers.Pharmaceutics · 2025Review
- Innovative Theranostics Strategies in the Fight Against Lung Cancer.Mini reviews in medicinal chemistry · 2025Review
- Applications of Novel Microscale and Nanoscale Materials for Theranostics: From Design to Clinical Translation.Pharmaceutics · 2024Review
- Hybrid Nanosystem Formed by DOX-Loaded Liposomes and Extracellular Vesicles from MDA-MB-231 Is Effective against Breast Cancer Cells with Different Molecular Profiles.Pharmaceutics · 2024Article
- Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges.Life (Basel, Switzerland) · 2024Review
- Graphene Oxide (GO) for the Treatment of Bone Cancer: A Systematic Review and Bibliometric Analysis.Nanomaterials (Basel, Switzerland) · 2024Review
- Evaluation of New Folate Receptor-mediated Mitoxantrone Targeting LiposomesCurrent pharmaceutical biotechnology · 2024Article
- Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses.Anti-cancer agents in medicinal chemistry · 2024Review
- Folate-chitosan Coated Quercetin Liposomes for Targeted Cancer Therapy.Current pharmaceutical biotechnology · 2024Article
- Development of doxorubicin-encapsulated magnetic liposome@PEG for treatment of breast cancer in BALB/c mice.Drug delivery and translational research · 2023Article
- Evaluation of acute toxicity and in vitro antitumor activity of a novel doxorubicin-loaded folate-coated pH-sensitive liposome.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Advances in lipid-based carriers for cancer therapeutics: Liposomes, exosomes and hybrid exosomes.Cancer letters · 2023Article
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Long circulating pH-sensitive liposomes have been shown to effectively deliver doxorubicin (DOX) to tumors and reduce its toxic effects. Folic acid receptors are upregulated in a wide variety of solid, epithelial tumors, including breast cancer. In order to improve liposomal endocytosis and antitumor activity, folic acid has been added to nanoparticles surfaces to exploit overexpression of folate receptors in tumor cells. The purpose of this study was to evaluate the antitumor activity in vitro and in vivo of long circulating pH-sensitive folate-coated DOX-loaded liposomes (SpHL-DOX-Fol) in a 4T1 breast cancer model system in vitro and in vivo. Biodistribution studies were performed and in vivo electrocardiographic parameters were evaluated. A higher tumor uptake for radiolabeled SpHL-Fol (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.